Amgen Fights FDA Over Proposed Tavneos Withdrawal With Hearing Request
Amgen formally requested an FDA hearing to contest a proposed withdrawal of Tavneos, citing benefits for vasculitis patients that outweigh the drug's risks.
Amgen is taking its case directly to federal regulators, filing a formal request for an FDA hearing to block the proposed withdrawal of Tavneos, its treatment for ANCA-associated vasculitis — a rare and potentially life-threatening inflammation of blood vessels. The move signals that the pharmaceutical giant is prepared to mount a rigorous defense of the drug rather than accept a regulatory retreat quietly.
At the core of Amgen's argument is a benefit-risk calculation the company believes tilts in patients' favor. ANCA-associated vasculitis carries serious consequences if left undertreated, and Amgen contends that the available clinical evidence supports Tavneos's continued place in the treatment landscape. The company has committed to submitting detailed supporting data and analysis to the FDA by June 29, 2026, framing the hearing process as an opportunity for thorough scientific review rather than a bureaucratic formality.
Read more DOJ Clears Paramount-WBD Merger in Major Media Consolidation →
Notably, Amgen is also calling for meaningful participation from patients and other stakeholders in the decision-making process — an increasingly common advocacy strategy in high-stakes drug disputes, where patient-reported outcomes and lived experience can carry real weight with regulators. This approach reflects a broader industry recognition that FDA proceedings are not purely technical exercises but also forums where public health values are weighed.
Despite the regulatory uncertainty surrounding one of its products, market reaction was muted. Amgen shares slipped just 0.05% to $357.32 at the time of publication, suggesting investors view the hearing request as a credible path forward rather than a signal of imminent commercial loss. Whether the FDA ultimately agrees with Amgen's benefit-risk framing will depend heavily on the data package the company presents ahead of the June 2026 deadline.
Continue reading at Benzinga.
